

Merja H Voutilainen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7100814/publications.pdf>

Version: 2024-02-01

27
papers

1,824
citations

394421

19
h-index

580821

25
g-index

29
all docs

29
docs citations

29
times ranked

1875
citing authors

#	ARTICLE	IF	CITATIONS
1	Antennas and Wireless Power Transfer to Small Biomedical Brain Implants. , 2022, , .		1
2	Double Split Rings as Extremely Small and Tuneable Antennas for Brain Implantable Wireless Medical Microsystems. IEEE Transactions on Antennas and Propagation, 2021, 69, 760-768.	5.1	22
3	MANF Is Neuroprotective in Early Stages of EAE, and Elevated in Spinal White Matter by Treatment With Dexamethasone. Frontiers in Cellular Neuroscience, 2021, 15, 640084.	3.7	7
4	Neuroprotective Potential of a Small Molecule RET Agonist in Cultured Dopamine Neurons and Hemiparkinsonian Rats. Journal of Parkinson's Disease, 2021, 11, 1023-1046.	2.8	8
5	Cerebral dopamine neurotrophic factor reduces α -synuclein aggregation and propagation and alleviates behavioral alterations in <i>Á</i> vivo. Molecular Therapy, 2021, 29, 2821-2840.	8.2	26
6	Netrin-1 and its receptor DCC modulate survival and death of dopamine neurons and Parkinson's disease features. EMBO Journal, 2021, 40, e105537.	7.8	32
7	Glial Cell Line-Derived Neurotrophic Factor Receptor Rearranged During Transfection Agonist Supports Dopamine Neurons <i>in Vitro</i> and Enhances Dopamine Release <i>in Vivo</i> . Movement Disorders, 2020, 35, 245-255.	3.9	24
8	Survival and Motor Phenotypes in FVB C9-500 ALS/FTD BAC Transgenic Mice Reproduced by Multiple Labs. Neuron, 2020, 108, 784-796.e3.	8.1	22
9	GDNF and Parkinson's Disease: Where Next? A Summary from a Recent Workshop. Journal of Parkinson's Disease, 2020, 10, 875-891.	2.8	63
10	GDNF Receptor Agonist Alleviates Motor Imbalance in Unilateral 6-Hydroxydopamine Model of Parkinson's Disease. , 2020, 1, 100004.		1
11	Cerebral Dopamine Neurotrophic Factor Diffuses Around the Brainstem and Does Not Undergo Anterograde Transport After Injection to the Substantia Nigra. Frontiers in Neuroscience, 2019, 13, 590.	2.8	7
12	Combination of CDNF and Deep Brain Stimulation Decreases Neurological Deficits in Late-stage Model Parkinson's Disease. Neuroscience, 2018, 374, 250-263.	2.3	27
13	Mesencephalic Astrocyte-Derived Neurotrophic Factor (MANF) Elevates Stimulus-Evoked Release of Dopamine in Freely-Moving Rats. Molecular Neurobiology, 2018, 55, 6755-6768.	4.0	11
14	Downregulation of tyrosine hydroxylase phenotype after AAV injection above substantia nigra: Caution in experimental models of Parkinson's disease. Journal of Neuroscience Research, 2018, 97, 346-361.	2.9	24
15	Pre- α -pro-GDNF and Pre- β -pro-GDNF Isoforms Are Neuroprotective in the 6-hydroxydopamine Rat Model of Parkinson's Disease. Frontiers in Neurology, 2018, 9, 457.	2.4	21
16	Implementation of deep neural networks to count dopamine neurons in substantia nigra. European Journal of Neuroscience, 2018, 48, 2354-2361.	2.6	38
17	Development and plasticity of meningeal lymphatic vessels. Journal of Experimental Medicine, 2017, 214, 3645-3667.	8.5	311
18	Evidence for an Additive Neurorestorative Effect of Simultaneously Administered CDNF and GDNF in Hemiparkinsonian Rats: Implications for Different Mechanism of Action. ENeuro, 2017, 4, ENEURO.0117-16.2017.	1.9	47

#	ARTICLE	IF	CITATIONS
19	Intrastrially Infused Exogenous CDNF Is Endocytosed and Retrogradely Transported to Substantia Nigra. <i>ENeuro</i> , 2017, 4, ENEURO.0128-16.2017.	1.9	32
20	Characterization of a new low-dose 6-hydroxydopamine model of Parkinson's disease in rat. <i>Journal of Neuroscience Research</i> , 2016, 94, 318-328.	2.9	39
21	Therapeutic potential of the endoplasmic reticulum located and secreted CDNF/MANF family of neurotrophic factors in Parkinson's disease. <i>FEBS Letters</i> , 2015, 589, 3739-3748.	2.8	71
22	Transient transfection of human CDNF gene reduces the 6-hydroxydopamine-induced neuroinflammation in the rat substantia nigra. <i>Journal of Neuroinflammation</i> , 2014, 11, 209.	7.2	56
23	Gene therapy with AAV-CDNF provides functional benefits in a rat model of Parkinson's disease. <i>Brain and Behavior</i> , 2013, 3, 75-88.	2.2	72
24	CDNF Protects the Nigrostriatal Dopamine System and Promotes Recovery after MPTP Treatment in Mice. <i>Cell Transplantation</i> , 2012, 21, 1213-1223.	2.5	112
25	Chronic infusion of CDNF prevents 6-OHDA-induced deficits in a rat model of Parkinson's disease. <i>Experimental Neurology</i> , 2011, 228, 99-108.	4.1	118
26	Mesencephalic Astrocyte-Derived Neurotrophic Factor Is Neurorestorative in Rat Model of Parkinson's Disease. <i>Journal of Neuroscience</i> , 2009, 29, 9651-9659.	3.6	238
27	Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo. <i>Nature</i> , 2007, 448, 73-77.	27.8	382